Thanks TommyFlowers for posting info on Biogen and the link. I do not know about any collaboration with Ixico and Biogen for AD, but I thought I had read somewhere that Ixico were, or had been in collaborating with Biogen iro MS since 2015. I noticed a latter commentator on Bloomberg stated that a large part of Biogen’s revenue comes from a drug called Spinraza (iro MS), which is getting old, and that a new company called Novartis would be presenting a new gene therapy treatment for Spinal Muscular Atrophy (pos Zolgensma) soon, and added that this might be a major competitor to Spinraza. Given Biogen’s major setback today and possible loss of expected future profits from that failure and resulting falling SP, as well as a possible downturn in their revenue from sales of Spinraza then I imagine if Ixico are still in collaboration with Biogen they might experience some fallout from today’s events, if not soon, later on. Hopefully, not too much. I think we both agreed in previous posts that a consensus was developing that previous approaches to developing drugs that could tackle beta-amyloids was something that pharmas were moving away from. I assume Biogen’s trial had been going on for a while and was implemented before the current views about the lack of effectiveness of drugs trialled that could break-down amyloids plaques esp in elderly clients. However, notwithstanding today’s events I would have thought that in respect of AD trials and research that Ixico would not be much affected. Presumably, alternative ideas fro fiding cures for AD will continue but plaques and tangles will still be used as biomarkers to identify the presence and progression of AD. Therefore, would I be wrong in assuming that these proteins will continue to be used to identify suitable clients for trials and for monitoring purposes. In which case I assume that new trials would still benefit from Ixico’s data programs and mapping facilities. Is this assumption wrong?
Thanks for the replies. I agree TommyFlowers that trials have been pulled and results from other trials have in the main been disappointing, and that Ixico’s size and their reliance on a few large clients could make them vulnerable. However, their recent announcement of collaborating with Kings IRO the new Medical Imaging and AI centre, as well as the recent investments by 2 directors are for me encouraging. Especially, as some researchers are now suggesting that AD trials underpinned by assumptions of the role of amyloid-beta in AD, could be mistaken, and are instead now suggesting that there is a greater need for research to be undertaken to find out how and why memory loss happens, as well as research to develop better methods of prediction and prevention of AD through AI. Data Collection, Wearable devices, Mapping, Bio-Markers etc. In which case do these views not appear to bode well for Ixico and COG who are at the forefront of some of these technologies, esp given the potential demand both locally and internationally for these technologies which could be considerable? I waited until today to post because as I had hoped there might be some development announced from the Alzheimer’s Research UK Conference in Harrogate today that might have been posted on the web IRO AI etc. Alas so far, I haven’t been able to find anything specific.
I am new to investing in stocks and shares and have not posted on this board before or for that matter any board before until today. Therefore, please forgive my ignorance if I have not followed some kind of etiquette. I have followed this board for the last few months since I invested in DEBs and have gained a great deal of knowledge from the comments made by all. However, in view of the the criticism that has at times be levelled at Pearls I just wanted to say that I have found his comments very helpful and a source of encouragement. GLA
I hope no-one minds me joining BB. I am very new to investing and am learning more every day. I have never posted to any BB before and don’t have a Twitter or FB a/c so please forgive me if I accidently break some etiquette for posting on here - This is all new to me. I am currently holding 45K+ shares and have been for a little while now. Re the earlier post by oldtrader2 IRO Susan Lowther - I was concerned when Shares Magazine reported on 11/12/2018 that “Ixico said Tuesday that Susan Lowther had resigned from her position as CFO to pursue other business interests” from my research she now seems to have moved to Arecor Ltd, as their new CFO. She does not appear to have made a public statement about why she left, but perhaps a clue might be gleamed from her remark on her Linkedin a/c https://uk.linkedin.com/in/susanlowther about the book she enjoys reading entitled, “ Integrity is by far the most important asset of a leader“. This is complete speculation on my part.
Notwithstanding the above, I too like others on this BB have been impressed by the new contracts and contract extensions Ixico have secured, esp those over the last few months. I am also very encouraged by the latest Directors investments and the company has a strong FC position. Given all these events and the appointment of the new CFO I would not be surprised in the least if further news was just ‘round the corner that might see this SP fly.